Literature DB >> 2993366

Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

J S McDougal, L S Martin, S P Cort, M Mozen, C M Heldebrant, B L Evatt.   

Abstract

The virus that causes the acquired immunodeficiency syndrome (AIDS), human T lymphotropic virus/lymphadenopathy-associated virus (HTLV-III/LAV), was incubated at temperatures from 37 degrees to 60 degrees C and virus titer (ID-50) was determined over time by a microculture infectivity assay. The rate of thermal decay was consistent with first-order kinetics, and these data were used to construct a linear Arrhenius plot (r = 0.99), which was used to determine inactivation time as a function of temperature. In the liquid state, thermal decay was little affected by matrix (culture media, serum, or liquid Factor VIII). In the lyophilized state, the time required to reduce virus titer 10-fold (1 log) at 60 degrees C was 32 min compared with 24 s in the liquid state. HTLV-III/LAV in liquid antihemophilic Factor VIII or IX was lyophilized and heated according to commercial manufacturers' specifications. Infectious virus was undetectable with these regimens. Heat treatment should reduce or stop transmission of HTLV-III/LAV by commercial antihemophilic Factor VIII or IX.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993366      PMCID: PMC423922          DOI: 10.1172/JCI112045

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  4 in total

1.  Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV).

Authors:  J S McDougal; S P Cort; M S Kennedy; C D Cabridilla; P M Feorino; D P Francis; D Hicks; V S Kalyanaraman; L S Martin
Journal:  J Immunol Methods       Date:  1985-01-21       Impact factor: 2.303

2.  Recovery and inactivation of infectious retroviruses from factor VIII concentration.

Authors:  J A Levy; G Mitra; M M Mozen
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

3.  Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate.

Authors:  C Rouzioux; S Chamaret; L Montagnier; V Carnelli; G Rolland; P M Mannucci
Journal:  Lancet       Date:  1985-02-02       Impact factor: 79.321

4.  Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light.

Authors:  B Spire; D Dormont; F Barré-Sinoussi; L Montagnier; J C Chermann
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

  4 in total
  37 in total

1.  Lipid composition and fluidity of the human immunodeficiency virus.

Authors:  R C Aloia; F C Jensen; C C Curtain; P W Mobley; L M Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis.

Authors:  D P Allersma; E Roeffen; J A Van der Does; E Briët
Journal:  Pharm Weekbl Sci       Date:  1991-02-22

3.  Recommendations for preventing transmission of HIV in health care settings.

Authors: 
Journal:  CMAJ       Date:  1988-02-01       Impact factor: 8.262

4.  Effect of using heat-inactivated serum with the Abbott human T-cell lymphotropic virus type III antibody test.

Authors:  D L Jungkind; S A DiRenzo; S J Young
Journal:  J Clin Microbiol       Date:  1986-02       Impact factor: 5.948

5.  Absence of seroconversion for HTLV-III in haemophiliacs intensively treated with heat treated factor VIII concentrate.

Authors:  J van der Meer; S Daenen; G W van Imhoff; J T de Wolf; M R Halie
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-19

6.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

7.  HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate.

Authors:  R S Remis; M V O'Shaughnessy; C Tsoukas; G H Growe; M T Schechter; R W Palmer; D N Lawrence
Journal:  CMAJ       Date:  1990-06-01       Impact factor: 8.262

8.  Drug level monitoring in a double-blind multicenter trial: false-positive zidovudine measurements in AIDS clinical trials group protocol 019.

Authors:  D J Krogstad; M R Eveland; L L Lim; P A Volberding; B M Sadler
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 9.  Anaesthesia and the child with HIV infection.

Authors:  D Schwartz; T Schwartz; E Cooper; J Pullerits
Journal:  Can J Anaesth       Date:  1991-07       Impact factor: 5.063

Review 10.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.